Metabolic dysfunction–associated steatohepatitis (MASH) is the most common liver disease worldwide, and its prevalence is increasing rapidly.1 Yet, effective treatments for MASH remain scarce. Obesity plays a central role in MASH. Glucagon-like peptide-1 (GLP-1) receptor agonists are emerging as the most promising antiobesity treatments2 and could…
The New England Journal of Medicine: Search Results in Gastroenterology
